高血压左室肥厚患者血浆sTRAIL、sDR4、sDR5水平的变化(英文)

目的:测定高血压左室肥厚患者血浆肿瘤坏死因子相关的凋亡诱导配体(sTRAIL)、及其死亡受体(sDR4、sDR5)水平。方法:用酶联免疫吸附法(ELISA)分别检测50例高血压左室肥厚患者(高血压左室肥厚组)、50例高血压无左室肥厚患者(高血压组)和50例健康人(健康对照组)血浆sTRAIL、sDR4和sDR5水平。结果:①与健康对照组及高血压组比较,高血压左室肥厚组血浆sTRAIL(0.95±0.11)ng/ml比(1.12±0.86)ng/ml比(1.74±1.19)ng/ml]、sDR4(2.38±0.32)pg/ml比(5.63±1.05)pg/ml比(8.72±1.14)pg/ml]、sDR5(<6 pg/ml)比(39.19±8.23)pg/ml比(78.21±11.2)pg/ml]水平均明显升高(P<0.01);且高血压组sDR4、sDR5水平明显高于健康对照组(P<0.01),sTRAIL水平与健康对照组无明显差异(P>0.05);②Pear-son相关分析表明,高血压左室肥厚患者sTRAIL、sDR4、sDR5间呈显著的正相关性(r=0.325～0.410,P<0.05或<0.01)。结论:血浆sTRAIL、sDR4、sDR5水平可能是预测高血压患者左室肥厚有价值的指标之一。

Changes of plasma levels of sTRAIL and its DR4, DR5 in hypertension patients with left ventricular hypertrophy

Objective： To determine plasma levels of soluble tumor necrosis factor-related apoptosis inducing ligand （sTRAIL） and its soluble death receptor （sDR4, sDR5） in essential hypertension （EH） patients with left ventricu- lar hypertrophy （LVH）. Methods： Enzyme linked immunosorbent assay （ELISA） was used to measure plasma levels of sTRAIL, sDR4 and sDR5 in 50 EH ＋ LVH patients （EH ＋ LVH group）, 50 EH patients without LVH （EH group） and 50 healthy subjects （healthy control group）, and the results were compared ＇and analyzed among three groups. Results： O Compared with healthy control group and EH group, there were significant increase in plasma levels of sTRAIL （0.95±0.11） ng/ml vs. （1.12±0.86） ng/ml vs. （1.74±1.19） ng/ml], sDR4 （2.38±0.32） pg/ml vs. （5.63±1.05） pg/ml vs. （8.72±1.14） pg/ml] and sDR5 （〈 6 pg/ml） vs. （39.19±8.23） pg/ml vs. （78.21±11.2） pg/ml] in EH ＋ LVH group, P〈0.01 all] and levels of sDR4 and sDR5 in EH group were signifi- cantly higher than those of healthy control group （P 〈 0.01 both）, but there was no significant difference in sTRAIL level between the two groups （P〉0.05） ; 2） Pearson correlation analysis indicated that there were signifi- cant positive correlation among levels of sTRAIL, sDR4 and sDR5 in EH ＋ LVH patients （r =0. 325~0. 410, P〈 0. 05 or 〈0. 01）. Conclusion： Plasma levels of sTRA/L, sDR4 and sDR5 may be valuable indexes for prediction of left ventricular hypertrophy in patients with hypertension.